Mesoblast shares tank after US FDA rejects cell therapy for children
Changes dateline, adds share movement in paragraph 1 and 3
Aug 4 (Reuters) -The U.S. health regulator rejected Mesoblast's MSB.AX, MESO.O cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, sending its Australia-listed shares crashing about 58% on Friday.
The U.S. Food and Drug Administration (FDA) required more data to support marketing approval for the company's lead product remestemcel-L, Mesoblast said in a statement on Thursday.
Mesoblast shares slumped as much as 58.3% when they opened in Sydney, before marginally paring some losses to trade down 54.8% at A$0.49 by 0416 GMT.
The rejection is a blow to Mesoblast's hopes for a potential launch of the therapy, especially after its fundraising efforts over the last two years.
The drug developer was seeking the FDA's approval for a cell therapy to treat children with a type of graft versus host disease (GvHD), whose symptoms did not respond to standard steroid therapy or developed recurrence while continuing treatment.
There are no approved therapies in children for the condition in which the donor's bone marrow or stem cells attack the recipient.
Reporting by Pratik Jain, Sriparna Roy and Shivani Tanna in Bengaluru; Additional reporting by Juby Babu; Editing by Krishna Chandra Eluri, Sherry Jacob-Phillips and Rashmi Aich
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
